NCT07202507Recruiting
Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether the Snoezelen multisensory relaxation approach can reduce anxiety symptoms in children and adolescents aged 8 to 17 years hospitalized for chemotherapy in a pediatric oncology unit. Researchers will compare patients' symptoms during a chemotherapy cycle with Snoezelen sessions to a previous cycle without Snoezelen, in order to assess changes in psychological and physical well-being. Participants will: * Be enrolled between their first (without Snoezelen) and second (with Snoezelen) chemotherapy cycles * Complete self-report questionnaires on anxiety, depression, quality of life, and nausea * Receive 45-minute Snoezelen sessions every two days during their second hospitalization * Participate in a semi-structured interview after the final session * Provide data on medications (anxiolytics, antiemetics) and vomiting frequency during both hospitalizations
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 1 Jul 2025
- Start date
- Sept 2027
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Centre Oscar Lambret
- Diseases
- Childhood cancers
- NCT number
- NCT07202507
What you commit to
- Study type: Interventional
- Planned participants: 20
- From Sept 2027 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindication to SNOEZELEN:
- Claustrophobia
- Presence of psychiatric, addictive or cognitive disorders that would prevent compliance with the protocol requirements;
Other
- State of health not allowing participation in the study (severe fatigue, symptoms refractory to treatment).
- Pregnant or breast-feeding women
Who the study is looking for
- New patient
- Treated in the Paediatrics/AJA department of the Oscar Lambret Centre for cancer (all types of cancer)
- Hospitalisation for several days
- Highly emetogenic chemotherapy treatment: this corresponds to all in-patient treatments carried out in the Paediatrics/AJA department.
- Age at diagnosis : ≥ 8 years and \< 18 years.
- French language
- Information for the patient and those with parental authority; consent signed by the patient and those with parental authority.
- Valid social security cover
Age in the registry: 8 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.